ReviewDrug design, development and therapy2025
Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents' Delivery Against Lung Cancer: A Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality and morbidity worldwide. Despite significant advancements in diagnostic techniques and therapeutic modalities such as surgery, chemotherapy, and radiotherapy, there is an urgent need for innovative therapeutic approaches due to severe adverse reactions, escalating multidrug resistance, an increased risk of tumor recurrence, and the complexity of the tumor microenvironment (TME). Nanotechnology-based drug delivery systems have emerged as a novel strategy for lung cancer treatment by enhancing drug targeting, reducing toxic side effects, and improving bioavailability. Chitosan (CS) has emerged as a promising candidate material for anticancer drug delivery carriers due to its unique physicochemical properties, biocompatibility, and biodegradability. This review summarizes recent research progress on CS nanocarriers for lung cancer treatment and elucidates their challenges and future prospects for clinical transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.